Grow Pharma said it has started trials to extract cannabis-based medical products in the UK, making it only the second company to have done so after GW Pharmaceuticals (NASDAQ:GWPH).
Privately-owned distributor Grow, part of Grow Group Plc, said it is attempting to replicate and distribute cannabis-based medicinal products (CBMPs) for patients experiencing Brexit disruption to supplies.
Grow Pharma said it is already legally importing GMP produced Bedrocan flowers into the UK for distribution to medicinal cannabis patients.
Bedrocan strains are used to produce the cannabis oil that around 40 families were collecting from a Dutch pharmacy.
“A post-Brexit, sustainable and UK based solution for this problem is needed and we are ready to step up to help,” said Pierre van Weperen, Grow Pharma’s chief executive.
He also mentioned that when prescriptions come in, initial samples will be made available free of charge and, in future, prices will be significantly less than parents are used to paying.
Grow’s partner, IPS Pharma, will produce the cannabis oils at its certified production facility in Surrey.
“ This is an opportunity to establish a UK-based solution that can produce CBMPs to the highest possible standards,” said van Weperen.
“We will be using the exact same starting material these patients are used to. From a scientific standpoint there is no reason why the end result would differ significantly beyond any fluctuations that may have arisen already within the current production process,” explained Ashok Patel, a pharmacist at IPS Pharma.